Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
High TCL1 expression associated with poor prognosis in patients with DLBCL
Key clinical point: TCL1 protein expression indicated a poor prognosis in patients with DLBCL.
Major finding: Positive TCL1 expression and Ki-67 expression ≥ 50% independently predicted short PFS and overall survival (P < .05).
Study details: Immunochemistry analysis of 137 DLBCL tissue samples to examine the expression of TCL1.
Disclosures: The study was supported by the National Natural Science Foundation of China and the authors reported having no conflicts.
Citation:
Gao XH et al. Pathology - Research and Practice. 2020;216(2):152799.